Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease
Year: 2024
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: The prognostic role of plasma neurofilament light chain (NfL), phospho-tau, beta-amyloid, and GFAP is still debated in Parkinson's disease (PD). METHODS: Plasma p-tau181, p-tau231, Aβ1-40, Aβ1-42, GFAP, and NfL were measured by SIMOA in 136 PD with 2.9 + 1.7 years of follow-up and 76 controls. Differences in plasma levels between controls and PD and their correlation with clinical severity and progression rates were evaluated using linear regression analyses. RESULTS: Patients exhibited similar distribution of plasma biomarkers but higher P-tau181, P-tau231 and lower Aβ1-42 compared with controls. NfL and GFAP correlated with baseline motor and non-motor severity measures. At follow-up, NfL emerged as the best predictor of progression with marginal effect of GFAP and p-tau181 adjusting for age, sex, disease duration, and baseline motor severity. CONCLUSION: The present findings confirmed plasma NfL as best predictor of progression in PD, with a marginal role of p-tau181 and GFAP.
Source: Journal of Neurology
Institutions: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, King's College London, South London and Maudsley NHS Foundation Trust, Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, University of Padua, University of Science and Technology of China, Sahlgrenska University Hospital, Sorbonne Université, Institut des Sciences Moléculaires, Pitié-Salpêtrière Hospital, Institut du Cerveau, UCL Queen Square Institute of Neurology, University College London, University of Wisconsin–Madison, UK Dementia Research Institute
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,590
Funders: Office of Dietary Supplements, Alzheimer's Drug Discovery Foundation, Familjen Erling-Perssons Stiftelse, Stiftelsen för Gamla Tjänarinnor, EU Joint Programme – Neurodegenerative Disease Research, National Institute for Health and Care Research, University College London, European Commission, Ministero della Salute, Ministero dell’Istruzione, dell’Università e della Ricerca, Hjärnfonden, Vetenskapsrådet, Università degli Studi di Brescia, UK Dementia Research Institute, Associazione Italiana Ricerca Alzheimer, National Institutes of Health, Horizon 2020 Framework Programme, UCLH Biomedical Research Centre, National Institute on Aging, H2020 European Research Council, H2020 Marie Skłodowska-Curie Actions, HORIZON EUROPE Reforming and enhancing the European Research and Innovation system
Awards: G1057200632, G1088883541, G1253720191, G1551449788, G1605148257, G1833008592, G2057385626, G2108271864, G2385484910, G2799940023, The Alzheimer biomarker toolbox – use in pathogenic studies, diagnostics and theragnostics, G2841269746, G292763017, G3241251457, Fluid biomarkers for neurodegenerative dementias, G3903502641, G4181470480, G4234328627, G4937468798, G5304458214, Identification and validation of COmmon pathways at the CrOssrOads of neurodegeneration and Neuroprotection (COCOON), G56684467, G581591135, CASCADE: CAuSe or Consequence in Alzheimer DiseasE?, Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis, G6289970089, G6984825484, G762836129, G8082854607, G8858395165, Arizona Alzheimer's Disease Research Center, G948514724, G958583170, G96521508
OpenAlex ID: W4402356881